Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned an average rating of “Moderate Buy” from the fifteen research firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $45.8462.

Several analysts have recently issued reports on the stock. Clear Str lowered shares of Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Barclays lowered Janux Therapeutics from an “overweight” rating to an “underweight” rating and decreased their price objective for the company from $29.00 to $14.00 in a research note on Monday, April 20th. Weiss Ratings upgraded Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. Truist Financial upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Monday, May 4th. Finally, JonesTrading decreased their price objective on Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, April 28th.

Janux Therapeutics Price Performance

Shares of JANX opened at $13.89 on Tuesday. The firm has a market cap of $847.01 million, a PE ratio of -7.55 and a beta of 2.58. The stock’s fifty day moving average price is $14.42 and its two-hundred day moving average price is $17.02. Janux Therapeutics has a 1 year low of $12.12 and a 1 year high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.13. The business had revenue of $3.73 million during the quarter, compared to the consensus estimate of $4.36 million. Sell-side analysts anticipate that Janux Therapeutics will post -1.71 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Maria Dobek sold 2,038 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $14.17, for a total transaction of $28,878.46. Following the sale, the vice president directly owned 32,270 shares in the company, valued at approximately $457,265.90. The trade was a 5.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 7.90% of the company’s stock.

Institutional Trading of Janux Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of JANX. State Street Corp increased its holdings in Janux Therapeutics by 103.8% during the 4th quarter. State Street Corp now owns 3,853,951 shares of the company’s stock worth $53,185,000 after acquiring an additional 1,962,486 shares during the period. Prosight Management LP increased its stake in Janux Therapeutics by 176.5% in the 4th quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock worth $33,017,000 after acquiring an additional 1,527,173 shares during the last quarter. Wellington Management Group LLP increased its stake in Janux Therapeutics by 129.5% in the 4th quarter. Wellington Management Group LLP now owns 1,610,186 shares of the company’s stock worth $22,221,000 after acquiring an additional 908,582 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in Janux Therapeutics in the 4th quarter worth about $12,221,000. Finally, Alyeska Investment Group L.P. increased its stake in Janux Therapeutics by 206.3% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,301,089 shares of the company’s stock worth $17,955,000 after acquiring an additional 876,244 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.